title: Sildenafil citrate, bronchopulmonary dysplasia and disordered pulmonary gas exchange: any benefits?
abstract: OBJECTIVE
  The objective of this study is to determine the effects that sildenafil citrate has on gas exchange in infants with bronchopulmonary dysplasia (BPD)-associated pulmonary hypertension (PH).
  
  
  METHODS
  A retrospective review was performed from 2005 to 2009. Infants treated with sildenafil citrate for greater than 48  h were included. Standard patient data was collected, including echocardiogram, inspired oxygen and systemic blood pressure, before and during administration of sildenafil citrate.
  
  
  RESULTS
  Sildenafil citrate was used in 21 preterm infants with BPD-associated PH. A significant reduction in estimated right ventricular peak systolic pressure was seen after initiation of sildenafil citrate, with the majority of infants showing no improvement in gas exchange at 48  h of treatment. Four infants died during treatment.
  
  
  CONCLUSIONS
  Sildenafil citrate reduced estimated pulmonary artery pressures, but this reduction was not reflected in improved gas exchange within the first 48  h.
authors.affiliation: Department of Pediatrics, Children's Mercy Hospital and Clinics, University of Missouri-Kansas City School of Medicine, Kansas City, MO, USA. mfnyp@cmh.edu
authors.forename: M
authors.initials: M
authors.lastname: Nyp
authors.forename: T
authors.initials: T
authors.lastname: Sandritter
authors.forename: N
authors.initials: N
authors.lastname: Poppinga
authors.forename: C
authors.initials: C
authors.lastname: Simon
authors.forename: W E
authors.initials: WE
authors.lastname: Truog
mesh_terms: D001997:Bronchopulmonary Dysplasia / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D005260:Female; D005865:Gestational Age; D006801:Humans; D006976:Hypertension, Pulmonary / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D007231:Infant, Newborn; D007234:Infant, Premature; D008297:Male; D058986:Phosphodiesterase 5 Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D010879:Piperazines / Q000494:pharmacology / Q000627:therapeutic use*; D011659:Pulmonary Gas Exchange / Q000187:drug effects*; D011687:Purines / Q000494:pharmacology / Q000627:therapeutic use; D012189:Retrospective Studies; D012720:Severity of Illness Index; D000068677:Sildenafil Citrate; D013450:Sulfones / Q000494:pharmacology / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D058986:Phosphodiesterase 5 Inhibitors; D010879:Piperazines; D011687:Purines; D013450:Sulfones; D000068677:Sildenafil Citrate